SE Wenzel, JB Trudeau, DA Kaminsky, J Cohn, RJ Martin and JY Westcott
Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206, USA.

To investigate the contribution of leukotrienes (LTs) to inflammation and bronchoconstriction in nocturnal asthma, we performed a randomized trial in 12 asthmatic patients and 6 normal control subjects. This study involved pulmonary function testing, methacholine challenge, bronchoscopy for cell counts, LT and thromboxane (TX) levels in bronchoalveolar lavage (BAL) fluid, and collection of urine for LTs at 4:00 P.M. and 4:00 A.M. At 4:00 P.M. BAL fluid LTB4 and sulfidopeptide LT levels in asthmatic and control subjects were not statistically different. At 4:00 A.M. alone, LTB4 and cysteinyl LT levels increased to become significantly greater in asthmatic than in control subjects, LTB4 levels correlating significantly (r = -0.66, p < 0.0001) with nocturnal fall in FEV1. Nocturnal asthmatic urinary LTE4 levels were also significantly higher than those of control subjects. The 4:00 A.M. testing was repeated during treatment with a 5-lipoxygenase inhibitor, zileuton. In asthmatic subjects, zileuton decreased BAL fluid LTB4 (p = 0.01) and urinary LTE4 (p = 0.01) while showing a trend for improving nocturnal FEV1 (p = 0.086). These decreases in LTB4 levels and improvement in FVE1 were associated with significant reductions in 4 A.M. BAL fluid and blood eosinophil percentages on zileuton compared with placebo administration. These findings demonstrate the importance of LTs in both the inflammation and the physiology of nocturnal asthma.

This article has been cited by other articles:

				M. Peters-Golden and W. R. Henderson Jr. Leukotrienes N. Engl. J. Med., November 1, 2007; 357(18): 1841 - 1854. [Full Text] [PDF]

				C. Taube, N. Miyahara, V. Ott, B. Swanson, K. Takeda, J. Loader, L. D. Shultz, A. M. Tager, A. D. Luster, A. Dakhama, et al. The Leukotriene B4 Receptor (BLT1) Is Required for Effector CD8+ T Cell-Mediated, Mast Cell-Dependent Airway Hyperresponsiveness. J. Immunol., March 1, 2006; 176(5): 3157 - 3164. [Abstract] [Full Text] [PDF]

				C. K. Grissom, L. D. Richer, and M. R. Elstad The Effects of a 5-Lipoxygenase Inhibitor on Acute Mountain Sickness and Urinary Leukotriene E4 After Ascent to High Altitude Chest, February 1, 2005; 127(2): 565 - 570. [Abstract] [Full Text] [PDF]

				P Cap, J Chladek, F Pehal, M Maly, V Petru, P J Barnes, and P Montuschi Gas chromatography/mass spectrometry analysis of exhaled leukotrienes in asthmatic patients Thorax, June 1, 2004; 59(6): 465 - 470. [Abstract] [Full Text] [PDF]

				J. Haynes Jr, B. S. Baliga, B. Obiako, S. Ofori-Acquah, and B. Pace Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway Blood, May 15, 2004; 103(10): 3945 - 3950. [Abstract] [Full Text] [PDF]

				S. Tanaka, H. Tanaka, and S. Abe High Dose of Inhaled Fluticasone Reduces High Levels of Urinary Leukotriene E4 in the Early Morning in Mild and Moderate Nocturnal Asthma Chest, November 1, 2003; 124(5): 1768 - 1773. [Abstract] [Full Text] [PDF]

				K. Kurokawa, H. Tanaka, S. Tanaka, and S. Abe Circadian Characteristics of Urinary Leukotriene E4 in Healthy Subjects and Nocturnal Asthmatic Patients Chest, December 1, 2001; 120(6): 1822 - 1828. [Abstract] [Full Text] [PDF]

				H. Bisgaard Leukotriene Modifiers in Pediatric Asthma Management Pediatrics, February 1, 2001; 107(2): 381 - 390. [Abstract] [Full Text]

				E. LEE, T. ROBERTSON, J. SMITH, and S. KILFEATHER Leukotriene Receptor Antagonists and Synthesis Inhibitors Reverse Survival in Eosinophils of Asthmatic Individuals Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 1881 - 1886. [Abstract] [Full Text]

				J. D. HASDAY, S. S. MELTZER, W. C. MOORE, P. WISNIEWSKI, J. RICHARD HEBEL, C. LANNI, L. M. DUBÉ, and E. R. BLEECKER Anti-inflammatory Effects of Zileuton in a Subpopulation of Allergic Asthmatics Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1229 - 1236. [Abstract] [Full Text]

				P. M. O'BYRNE Why Does Airway Inflammation Persist? Is It Leukotrienes? Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): S186 - 187. [Full Text] [PDF]

				M. KUMLIN Measurement of Leukotrienes in Humans Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): S102 - 106. [Full Text] [PDF]

				S. T. HOLGATE and A. P. SAMPSON Antileukotriene Therapy . Future Directions Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): S147 - 153. [Full Text] [PDF]

				T. Casale Immunobiology of Asthma and Rhinitis . Pathogenic Factors and Therapeutic Options Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1778 - 1787. [Full Text]

				M. A. Giembycz and M. A. Lindsay Pharmacology of the Eosinophil Pharmacol. Rev., June 1, 1999; 51(2): 213 - 340. [Abstract] [Full Text] [PDF]

				S. E. Wenzel Antileukotriene Drugs in the Management of Asthma JAMA, December 23, 1998; 280(24): 2068 - 2069. [Full Text] [PDF]

				S. E. WENZEL Should Antileukotriene Therapies Be Used Instead of Inhaled Corticosteroids in Asthma? . No Am. J. Respir. Crit. Care Med., December 1, 1998; 158(6): 1699 - 1701. [Full Text] [PDF]

				H. W. CHU, J. L. HALLIDAY, R. J. MARTIN, D. Y. M. LEUNG, S. J. SZEFLER, and S. E. WENZEL Collagen Deposition in Large Airways May Not Differentiate Severe Asthma from Milder Forms of the Disease Am. J. Respir. Crit. Care Med., December 1, 1998; 158(6): 1936 - 1944. [Abstract] [Full Text] [PDF]

				P. J. Barnes, K. F. Chung, and C. P. Page Inflammatory Mediators of Asthma: An Update Pharmacol. Rev., December 1, 1998; 50(4): 515 - 596. [Abstract] [Full Text] [PDF]

				W.-W. Huang, E. A. Garcia-Zepeda, A. Sauty, H. C. Oettgen, M. E. Rothenberg, and A. D. Luster Molecular and Biological Characterization of the Murine Leukotriene B4 Receptor Expressed on Eosinophils J. Exp. Med., September 21, 1998; 188(6): 1063 - 1074. [Abstract] [Full Text] [PDF]

				R. J. MARTIN and S. BANKS-SCHLEGEL Chronobiology of Asthma Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 1002 - 1007. [Full Text] [PDF]

				T. Fournier, V. Fadok, and P. M. Henson Tumor Necrosis Factor-alpha Inversely Regulates Prostaglandin D2 and Prostaglandin E2 Production in Murine Macrophages. SYNERGISTIC ACTION OF CYCLIC AMP ON CYCLOOXYGENASE-2 EXPRESSION AND PROSTAGLANDIN E2 SYNTHESIS J. Biol. Chem., December 5, 1997; 272(49): 31065 - 31072. [Abstract] [Full Text] [PDF]

				S. E. WENZEL, S. J. SZEFLER, D. Y. M. LEUNG, S. I. SLOAN, M. D. REX, and R. J. MARTIN Bronchoscopic Evaluation of Severe Asthma . Persistent Inflammation Associated with High Dose Glucocorticoids Am. J. Respir. Crit. Care Med., September 1, 1997; 156(3): 737 - 743. [Abstract] [Full Text] [PDF]

				J. DRAZEN Clinical Pharmacology of Leukotriene Receptor Antagonists and 5-Lipoxygenase Inhibitors Am. J. Respir. Crit. Care Med., June 1, 1997; 157(6): 233S - 237. [Abstract] [Full Text]

				R. J. HORWITZ, K. A. MCGILL, and W. W. BUSSE The Role of Leukotriene Modifiers in the Treatment of Asthma Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1363 - 1371. [Full Text]

				W. J. CALHOUN, B. J. LAVINS, M. C. MINKWITZ, R. EVANS, G. J. GLEICH, and J. COHN Effect of Zafirlukast (Accolate) on Cellular Mediators of Inflammation . Bronchoalveolar Lavage Fluid Findings after Segmental Antigen Challenge Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1381 - 1389. [Abstract] [Full Text]

				F. P. GÓMEZ, R. IGLESIA, J. ROCA, J. A. BARBERÁ, K. FAN CHUNG, and R. RODRIGUEZ-ROISIN The Effects of 5-Lipoxygenase Inhibition by Zileuton on Platelet-activating-factor-induced Pulmonary Abnormalities in Mild Asthma Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1559 - 1564. [Abstract] [Full Text]

				R. L. Bell, R. R. Harris, P. E. Malo, J. B. Bouska, T. K. Shaughnessy, K. I. Hulkower, C. D. W. Brooks, and G. W. Carter ABT-761 Attenuates Bronchoconstriction and Pulmonary Inflammation in Rodents J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1366 - 1373. [Abstract] [Full Text]